The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
Open accessAbstract
Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients 1 , yet harbours mutation-derived T cell neoantigens that are suitable for vaccines 2,3 . Here in a phase I trial of adjuvant autogene cevumeran, an individualized neoantigen vaccine based on uridine mRNA–lipoplex nanoparticles, we synthesized mRNA neoantigen vaccines in real time from surgically resected PDAC tumours. After surgery, we sequentially administered atezolizumab (an anti-PD-L1 immunotherapy), autogene cevumeran (a maximum of 20 neoantigens per patient) and a modified version of a four-drug chemotherapy regimen (mFOLFIRINOX, comprising folinic acid, fluorouracil, irinotecan and oxaliplatin). The end points included vaccine-induced neoantigen-specific T cells by high-threshold assays, 18-month recurrence-free survival and oncologic feasibility. We treated 16 patients with atezolizumab and autogene cevumeran, then 15 patients with mFOLFIRINOX. Autogene cevumeran was administered within 3 days of benchmarked times, was tolerable and induced de novo high-magnitude neoantigen-specific T cells in 8 out of 16 patients, with half targeting more than one vaccine neoantigen. Using a new mathematical strategy to track T cell clones (CloneTrack) and functional assays, we found that vaccine-expanded T cells comprised up to 10% of all blood T cells, re-expanded with a vaccine booster and included long-lived polyfunctional neoantigen-specific effector CD8 + T cells. At 18-month median follow-up, patients with vaccine-expanded T cells (responders) had a longer median recurrence-free survival (not reached) compared with patients without vaccine-expanded T cells (non-responders; 13.4 months, P = 0.003). Differences in the immune fitness of the patients did not confound this correlation, as responders and non-responders mounted equivalent immunity to a concurrent unrelated mRNA vaccine against SARS-CoV-2. Thus, adjuvant atezolizumab, autogene cevumeran and mFOLFIRINOX induces substantial T cell activity that may correlate with delayed PDAC recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures














Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although further confirmatory studies are needed, these results provide initial clinical evidence that personalized therapeutic cancer vaccines can enhance responses to ICIs, with many other studies planned.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [136]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In this trial, 8 of 16 patients with resected pancreatic ductal adenocarcinoma remained free of cancer after a median follow-up of 18 months136.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [136]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cancer mRNA-based vaccines tend to be administered alone or in combination with ICIs, and after resection, although they have also been used in neoadjuvant–adjuvant treatment approaches136,138,139 (Fig. 3c,d).”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [136]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“patients enrolled in the trial with an immunologic response against the vaccine had longer median RFS than those without such a response136.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [136]
The cited source says what the claim attributes to it.
In the citing paper
“Clinical trials of mRNA-based immunotherapeutics encoding unmutated full-length TAAs in checkpoint inhibitor-treated melanoma [18] and individualised mRNA-based immunotherapeutics encoding patient-specific mutated tumour neoantigens in pancreatic and lung cancer [19, 20] have shown encouraging results.”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [20]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
SCANPY: large-scale single-cell gene expression data analysis
Wolf, F. A., Angerer, P., & Theis, F. J. (2018) · Genome Biology · doi:10.1186/s13059-017-1382-0 · Cited by 8,881
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Self-citationCOSMIC: the Catalogue Of Somatic Mutations In Cancer
Tate, J. G., Bamford, S., Jubb, H. C., Sondka, Z., Beare, D. M., Bindal, N., Boutselakis, H., Cole, C. G., Creatore, C., Dawson, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1015 · Cited by 4,867
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Cited by
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
The cancer-immunity cycle: Indication, genotype, and immunotype
Mellman, I., Chen, D. S., Powles, T., & Turley, S. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.011 · Cited by 953
Self-citationStoop, T. F., Javed, A. A., Oba, A., Koerkamp, B. G., Seufferlein, T., Wilmink, J. W., & Besselink, M. G. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00261-2 · Cited by 479
Therapeutic cancer vaccines: Advancements, challenges, and prospects
Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., & Dong, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01674-3 · Cited by 597
Huang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 490
Metadata
- Authors
- Rojas, L. A., Sethna, Z., Soares, K. C., Olcese, C., Pang, N., Patterson, E., Lihm, J., Ceglia, N., Guasp, P., Chu, A., Yu, R., Chandra, A. K., Waters, T., Ruan, J., Amisaki, M., Zebboudj, A., Odgerel, Z., Payne, G., Derhovanessian, E., Müller, F., Rhee, I., Yadav, M., Dobrin, A., Sadelain, M., Łuksza, M., Cohen, N., Tang, L., Basturk, O., Gönen, M., Katz, S., Do, R. K., Epstein, A. S., Momtaz, P., Park, W., Sugarman, R., Varghese, A. M., Won, E., Desai, A., Wei, A. C., D’Angelica, M. I., Kingham, T. P., Mellman, I., Merghoub, T., Wolchok, J. D., Sahin, U., Türeci, Ö., Greenbaum, B. D., Jarnagin, W. R., Drebin, J., O’Reilly, E. M., & Balachandran, V. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- BioNTech (Germany) (DE)
- Genentech (US)
- Tisch Cancer Institute (US)
- Icahn School of Medicine at Mount Sinai (US)
- Weill Cornell Medicine (US)
- Corresponding author
- Greenbaum, Benjamin D.
- Balachandran, Vinod P.
- ORCID
- Rojas, Luis A.
- Sethna, Zachary
- Soares, Kevin C.
- Olcese, Cristina
- Lihm, Jayon
- Ceglia, Nicholas
- Guasp, Pablo
- Yu, Rebecca
- Amisaki, Masataka
- Zebboudj, Abderezak
- Yadav, Mahesh
- Dobrin, Anton
- Sadelain, Michel
- Łuksza, Marta
- Cohen, Noah
- Tang, Laura
- Basturk, Olca
- Gönen, Mithat
- Katz, Seth
- Epstein, Andrew S.
- Momtaz, Parisa
- Park, Wungki
- Varghese, Anna M.
- Won, Elizabeth
- Wei, Alice C.
- Kingham, T. Peter
- Mellman, Ira
- Merghoub, Taha
- Wolchok, Jedd D.
- Sahin, Ugur
- Türeci, Özlem
- Greenbaum, Benjamin D.
- Jarnagin, William R.
- Drebin, Jeffrey
- O’Reilly, Eileen M.
- Balachandran, Vinod P.
- Venue
- Nature
- Published
- 2023-05-10
- Volume
- 618
- Issue
- 7963
- Pages
- 144-150
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC10171177
- OpenAlex
- W4376133743
- Cited by
- 1,432
- References
- 63
- Citations by year
- 2026: 426 · 2025: 488 · 2024: 381 · 2023: 136
- FWCI
- 156.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Damon Runyon Cancer Research Foundation
- Lustgarten Foundation
- Pershing Square Sohn Cancer Research Alliance
- Cycle for Survival
- National Institutes of Health (CA08748, CCSG, P30 CA08748)
- Genentech
- Stand Up To Cancer
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology
- National Cancer Institute (U01CA224175, P30-CA-08748, CA08748, CA224175, P30CA008748, CCSG P30 CA08748)
- Moonshot Research and Development Program
- Cancer Moonshot
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- pancreatic ductal adenocarcinoma, personalized neoantigen vaccine, mRNA vaccines, atezolizumab, modified FOLFIRINOX, neoantigen-specific T cells, CD8+ T cells, recurrence-free survival, adjuvant immunotherapy, immune fitness, COVID-19 mRNA vaccine
- MeSH terms
- mRNA Vaccines, Adjuvants, Immunologic, Antigens, Neoplasm, Humans, Immunotherapy, Lymphocyte Activation, Pancreatic Neoplasms, T-Lymphocytes, CD8-Positive T-Lymphocytes, Cancer Vaccines, Carcinoma, Pancreatic Ductal, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. https://app.cochat.ai/papers/10.1038/s41586-023-06063-y
- The paper
- Rojas, L. A., Sethna, Z., Soares, K. C., Olcese, C., Pang, N., Patterson, E., Lihm, J., Ceglia, N., Guasp, P., Chu, A., Yu, R., Chandra, A. K., Waters, T., Ruan, J., Amisaki, M., Zebboudj, A., Odgerel, Z., Payne, G., Derhovanessian, E., . . . Balachandran, V. P. (2023). Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. https://doi.org/10.1038/s41586-023-06063-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.